Cadrenal Therapeutics Inc. Common Stock (CVKD)

FairStock Score: 42/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Looking at Cadrenal through a Graham-and-Buffett lens, I see a clinical-stage biotech, not a proven business. It reports no revenue. Filed losses are persistent: fiscal 2025, the year ended 2025-12-31, net loss was $13.2 million; fiscal 2024, the year ended 2024-12-31, net loss was $10.7 million; fiscal 2023, the year ended 2023-12-31, net loss was $8.4 million. In fiscal Q2 2026, the quarter ended 2026-06-30, it lost $3.3 million, or $1.14 per diluted share; in fiscal Q1 2026, the quarter ended 2026-03-31, it lost $2.5 million, or $1.04 per diluted share. Trailing free cash flow is -$10.2 million, a FCF yield of -285.8% against a $3.6 million market cap at the $1.00 close on 2026-10-13—cash consumption exceeds the entire equity value. At that same close, FairStock calculations show P/E -0.20, P/B 0.76, ROE -275.16%, ROCE -125.93%, Piotroski 1/9, and Altman Z -8.91. P/B below one may look cheap, but book value is not earning power, and there is no revenue to value. The only real asset is Tecarfarin's Phase 3 potential in chronic anticoagulation and CAD-1005. That is a binary scientific option, not a moat. Buffett wants durable advantages and predictable cash flows; Graham wants a margin of safety in earnings and assets. Here, the margin of safety is thin and depends on trial outcomes and financing. The FairStock Score of 42/100 and no Lynch category—because of losses in each of the last four years—confirm the fragility. I would call it speculative, not cheap.

In plain English: Cadrenal is a tiny drug company with no product sales yet. It is testing a medicine meant to prevent dangerous blood clots in people with serious heart and kidney conditions. The business is losing money and using cash, so although the share price is very low, the numbers do not show a profitable or clearly cheap company—just a risky bet on future trial results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer